An observational study in Breakthrough Cancer Pain, sponsored by A.Menarini Asia-Pacific Holdings Pte Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2022-05-05.
Sponsored by A.Menarini Asia-Pacific Holdings Pte Ltd (part of Menarini Group) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Cancer Pain with a site in Korea, Republic of — none open to participants now, none under way, none of them phase 3. Cancer Pain · Korea, Republic of.
Among the 15 studies in Cancer Pain with a site in Korea, Republic of, this one is one of 2 that started in 2017, is one of 2 observational ones, and was the 14th registered.
311 studies on the registry are indexed under Cancer Pain; 74 are open to participants now.
Browse Cancer Pain studies →None of the 15 studies in Cancer Pain with a site in Korea, Republic of is open now. The open studies under Cancer Pain, anywhere →
Of the 45 Cancer Pain studies recruiting now, 33 (73%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 143 is close to the median of 151 across 61 observational studies indexed under Cancer Pain.
Median enrollment 79 across the 13 interventional studies, 272 across the 2 observational. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under A.Menarini Asia-Pacific Holdings Pte Ltd, one of the names counted as Menarini Group. Under that name alone:
A.Menarini Asia-Pacific Holdings Pte Ltd is the lead sponsor of 5 studies on the registry; none are open to participants now.
Menarini Group has 1 study filed under Cancer Pain — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Cancer Pain with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this observational study is:
To observe the efficacy, safety, and tolerability of Abstral ODT for the alleviation of breakthrough cancer pain in Korean patients with various cancers in real-world clinical settings and supplement and expand the previous cross-sectional survey results.
This is a multicenter, non-interventional, single-arm, non-randomized observational study designed to collect the efficacy, safety, and tolerability data of Abstral ODT for the treatment of breakthrough cancer pain in cancer patients in real-world outpatient and inpatient clinical settings.
As the purpose of this study is to investigate the efficacy and safety of Abstral ODT in routine clinical practice, drug prescription and treatment will be determined according to the medical judgment of the investigator, regardless of enrollment to this study. During the patient's visit to the institution, Abstral ODT will be prescribed according to the judgment of the investigator, and study participation will be suggested for this patient. Whether to participate in this study or not will not affect the patient's treatment (physician's prescription or diagnostic and therapeutic decision).
Due to the non-interventional observational nature of this study, there will be no visits or procedures to be performed mandatorily according to the protocol, and data will be collected at Week 1 (±3 days), Week 4 (±1 week), and Week 12 (±4 weeks) from the baseline visit according to the circumstances of clinical practice.
Status of successful dose titration for Abstral ODT will be determined according to the criteria in which dose titration is deemed successful when all of the following are met, and ineffective when one of the following is not met: no additional dose is administered within 2 h of administration of Abstral ODT during maintenance phase; Numeric Rating Scale scores at 30 and 60 min after administration is reduced by ≥2; adverse drug reactions are tolerable for the subject.The overall procedures of this study are as follows.
Patients who have been regularly on treatment with opioids for cancer pain from before study initiation and have no prior treatment with Abstral ODT within 30 days prior to study initiation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In patient with Breakthrough cancer pain in inpatient or outpatient settings,
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Abstral Oral Disintegrating Tablet (ODT)
Drug: Abstral Oral Disintegrating Tablet (ODT)
Opioid(Fentanyl)
Also known as: Fentanyl
Number of Subjects of successful dose titration
Status of successful dose titration. Titration is considered successful when all of the following are met, and ineffective when one of the following is not met: * No additional dose is administered within 2 h of administration of Abstral ODT during maintenance phase; * Numeric Rating Scale scores at 30 mins after administration is reduced by ≥2; Numeric Rating Scale is to measure pain intensity in subject by verbally responding to a 10-point Numeric Rating Scale (0=no pain and 10=worst possible pain in total range) * Adverse drug reactions are tolerable for the subject.
Time frame: week 1
Number of Subjects of successful dose titration
Status of successful dose titration. Titration is considered successful when all of the following are met, and ineffective when one of the following is not met: * No additional dose is administered within 2 h of administration of Abstral ODT during maintenance phase; * Numeric Rating Scale scores at 30 mins after administration is reduced by ≥2; Numeric Rating Scale is to measure pain intensity in subject by verbally responding to a 10-point Numeric Rating Scale (0=no pain and 10=worst possible pain in total range) * Adverse drug reactions are tolerable for the subject.
Time frame: week 4
Number of Subjects of successful dose titration
Status of successful dose titration. Titration is considered successful when all of the following are met, and ineffective when one of the following is not met: * No additional dose is administered within 2 h of administration of Abstral ODT during maintenance phase; * Numeric Rating Scale scores at 30 mins after administration is reduced by ≥2; Numeric Rating Scale is to measure pain intensity in subject by verbally responding to a 10-point Numeric Rating Scale (0=no pain and 10=worst possible pain in total range) * Adverse drug reactions are tolerable for the subject.
Time frame: week 12
Status of achievement of Numeric Rating Scale goal
Status of achievement of Numeric Rating Scale goal set by each subject Numeric Rating Scale is to measure pain intensity in subject by verbally responding to a 10-point Numeric Rating Scale (0=no pain and 10=worst possible pain in total range)
Time frame: week 1
Abstral ODT maintenance dose
Abstral ODT maintenance dose at Week 4 and 12 of treatment, and after dose titration Data will be collected at Week 1 (±3 days), Week 4 (±1 week), and Week 12 (±4 weeks) from the baseline visit according to the circumstances of clinical practice.
Time frame: week 1(dose titration)
Abstral ODT maintenance dose
Abstral ODT maintenance dose at Week 4 and 12 of treatment, and after dose titration Data will be collected at Week 1 (±3 days), Week 4 (±1 week), and Week 12 (±4 weeks) from the baseline visit according to the circumstances of clinical practice.
Time frame: week 4
Abstral ODT maintenance dose
Abstral ODT maintenance dose at Week 4 and 12 of treatment, and after dose titration Data will be collected at Week 1 (±3 days), Week 4 (±1 week), and Week 12 (±4 weeks) from the baseline visit according to the circumstances of clinical practice.
Time frame: week 12
Brief Pain Inventory-Korean and Pain Diary values and changes
Brief Pain Inventory-Korean and Pain Diary values (maximum pain intensity of all incidences of breakthrough pain, pain intensity difference at 30min, pain intensity difference at 60 mins, quality of sleep, etc.) and changes. Brief Pain Inventory-Korean is to measure pain intensity in subject by verbally responding to a 10-point scale(0=no pain and 10=worst possible pain in total range)
Time frame: week 1
Brief Pain Inventory-Korean and Pain Diary values and changes
Brief Pain Inventory-Korean and Pain Diary values (maximum pain intensity of all incidences of breakthrough pain, pain intensity difference at 30min, pain intensity difference at 60 mins, quality of sleep, etc.) and changes. Brief Pain Inventory-Korean is to measure pain intensity in subject by verbally responding to a 10-point scale(0=no pain and 10=worst possible pain in total range)
Time frame: week 4
Brief Pain Inventory-Korean and Pain Diary values and changes
Brief Pain Inventory-Korean and Pain Diary values (maximum pain intensity of all incidences of breakthrough pain, pain intensity difference at 30min, pain intensity difference at 60 mins, quality of sleep, etc.) and changes. Brief Pain Inventory-Korean is to measure pain intensity in subject by verbally responding to a 10-point scale(0=no pain and 10=worst possible pain in total range)
Time frame: week 12
Plan to share: No
Ran from Jul 2017 to primary completion in Jun 2019, 23 months.
Of 26 observational studies under Cancer Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 40. This study's 23 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
A.Menarini Asia-Pacific Holdings Pte Ltd →